News & Events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01

10 September 2020

Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.

9 September 2020

Dr Timi Oshodi joined OncoArendi Therapeutics

3 July 2020

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship

13 May 2020

OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients

20 April 2020

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

24 March 2020

Events & Presentations

R&D Day Presentation, 07.12.2022

7 December 2022

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada

27 February 2020

EFMC-ASMC’19 – September 1-5, 2019 | Athens, Greece

11 September 2019

ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA

4 September 2019

ATS- International Conference – Dallas, 17-22.05.2019

22 May 2019

EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018

17 September 2018
This site is registered on as a development site.